跳至主要内容
临床试验/NCT00654225
NCT00654225已完成3 期

A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in South Asian Subjects.

AstraZeneca0 个研究点目标入组 2,340 人开始时间: 2002年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
2,340
主要终点
Low density lipoproteins cholesterol levels

研究概览

简要总结

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in South Asian subjects with hypercholesterolemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Fasting low density lipoprotein & triglyceride levels as defined by the protocol.
  • Self described South Asian race
  • Subjects with coronary heart disease or at high risk of coronary heart disease.

排除标准

  • The use of lipid lowering drugs or dietary supplements after Visit
  • Active arterial disease eg Unstable angina, or recent arterial surgery
  • Blood lipid levels above the limits defined in the protocol.
  • Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

研究组 & 干预措施

1

Experimental

Rosuvastatin

干预措施: Rosuvastatin (Drug)

2

Active Comparator

Atorvastatin

干预措施: Atorvastatin (Drug)

结局指标

主要结局

Low density lipoproteins cholesterol levels

时间窗: 6 weeks

次要结局

  • Safety: adverse events & abnormal laboratory markers(6 weeks)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验